# Vaccine Therapy in Treating Patients With Stage II Melanoma That Can Be Removed by Surgery

> **NCT00003274** · PHASE2 · COMPLETED · sponsor: **University of Southern California** · enrollment: 48 (actual)

## Conditions studied

- Melanoma (Skin)

## Interventions

- **BIOLOGICAL:** gp100 antigen
- **BIOLOGICAL:** incomplete Freund's adjuvant
- **BIOLOGICAL:** sargramostim
- **BIOLOGICAL:** tyrosinase peptide

## Key facts

- **NCT ID:** NCT00003274
- **Lead sponsor:** University of Southern California
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 1998-03
- **Primary completion:** 2001-09
- **Final completion:** 2002-11
- **Target enrollment:** 48 (ACTUAL)
- **Last updated:** 2014-05-22

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00003274

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00003274, "Vaccine Therapy in Treating Patients With Stage II Melanoma That Can Be Removed by Surgery". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT00003274. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*